logo
Sign in

Celldex Therapeutics

HAMPTON, NJ · Biotech · Public

Humanized monoclonal antibody (barzolvolimab) targeting KIT receptor tyrosine kinase to modulate mast cell function in inflammatory and autoimmune diseases

Claim this profile

Follows are private to you and power your alerts

Updated · celldex.com

Sector
Biotech
Headquarters
HAMPTON, NJ
Latest Form D
$62.5M, Nov 2016
Total capital
$68.1M
Federal grants
$5.4M
5 awards · 2015–2021
5.0× sector median 1 award
Private capital raised
$62.5M
1 Form D · last Nov 2016
119 months since last filing
Federal contracts
$199K
1 award · Health and Human S
Rank in Biotech#295 of 4373
Granted patents
19
21 pending · first 2019
Rank in peer group#81 of 1449

Capital timeline

20122014201620182020FEDERAL ↑EQUITY ↓Cumulative $68.1M$199K$988K$1.1M$539K$1.2M$1.6M1st Form D$62.5M
20122014201620182020FEDERAL ↑EQUITY ↓Cumulative $68.1M$988K$1.1M$1.2M$1.6M1st Form D$62.5M

Latest events

  • Federal grantHealth and Human S · Phase II · Immune modulation of radiation therapy with Flt3 ligand$1.6M
  • Federal grantHealth and Human S · Phase II · Immune modulation of radiation therapy with Flt3 ligand$1.2M
  • Private capital raisedForm D · SEC · 1st filing$62.5M
  • Federal grantHealth and Human S · Phase II · Immune modulation of radiation therapy with Flt3 ligand$539K
  • Federal grantHealth and Human S · Phase II · Immune modulation of radiation therapy with Flt3 ligand$1.1M
  • Federal grantHealth and Human S · Phase II · Dendritic Cell-Targeted HIV Vaccine Product$988K
  • Federal contractHealth and Human S · Igf::ot::igf Other Functions - R&d Biomedical (basic Research)$199K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

50months

from Celldex Therapeutics’s first federal award to its first private round.

First federal award · Sep 2012
Health and Human S · $199K
First Form D · Nov 2016
$62.5M · 1st Form D
Awards before first raise
4 awards

An association in public records, not a cause or a prediction.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#81 · top 6%
  • Linked publications#1 · top 1%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Anthony S. MarucciExecutive Officer, DirectorNamed in SEC Form D filings
  • Avery W. CatlinExecutive OfficerNamed in SEC Form D filings
  • George O. ElstonDirectorNamed in SEC Form D filings
  • Harry H. Penner, Jr.DirectorNamed in SEC Form D filings
  • Herbert J. ConradDirectorNamed in SEC Form D filings
  • Karen O. ShoosDirectorNamed in SEC Form D filings
Show all 9 people
  • Larry J. EllbergerDirectorNamed in SEC Form D filings
  • Richard H. van den BroekDirectorNamed in SEC Form D filings
  • Timothy M. Shannon, M. D.DirectorNamed in SEC Form D filings

What it has protected

USPTO · 19 granted of 40
  • PendingAgonistic Antibodies That Bind Human CD40 And Uses ThereofUSPTOApplication 19183513
  • PendingAnti-kit Antibody Formulations And MethodsUSPTOApplication 18998418
  • PendingANTI-PD-L1 Antibodies And Methods Of Use ThereofUSPTOApplication 18962161
Show all 40 patent records

Recent research by its founders

  • Abstract A052: Safety, immunogenicity and resistance of <i>in situ</i> Immunomodulation with CDX-301, radiotherapy, CDX-1140, and Poly-ICLC in patients with unresectable and metastatic solid tumors: a phase 1 trial20260 cites
  • Data from IL10R Inhibition Induces Neutrophil Tumoricidal Activity20260 cites
  • Figure S1 from IL10R Inhibition Induces Neutrophil Tumoricidal Activity20260 cites

Related companies, and why

  • Ursa AnalyticsSimilar federal contract value in Biotech · $205K in contracts
  • Avidity BiosciencesSimilar federal contract value in Biotech · $200K in contracts
  • TARGEPEUTICS, INC.Similar federal contract value in Biotech · $200K in contracts
  • Aura BiosciencesSimilar federal contract value in Biotech · $198K in contracts
  • GEOVAX, INC.Similar federal contract value in Biotech · $198K in contracts
  • Angiocrine BioscienceSimilar federal contract value in Biotech · $189K in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .